Want to see ACHV full AI Analyst Report?
ACHV Stock Chart & Stats
$8.17
$0.02(0.33%)
At close: 4:00 PM EDT
$8.17
$0.02(0.33%)
Day’s Range― - ―
52-Week Range$2.62 - $8.64
Previous CloseN/A
Volume586.58K
Average Volume (3M)1.29M
Market Cap
$873.64M
Enterprise Value$438.27
Total Cash (Recent Filing)$187.30M
Total Debt (Recent Filing)$14.95M
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Nov 05, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding102,902,490
10 Day Avg. Volume1,171,925
30 Day Avg. Volume1,291,941
Financial Highlights & Ratios
PEG Ratio-4.93
Price to Book (P/B)10.07
Price to Sales (P/S)0.00
P/FCF Ratio-4.38
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.17Price Target Upside73.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Nicotine-cessation PipelineA focused therapeutic strategy gives Achieve a clear development and commercialization objective rather than a fragmented portfolio. Cytisinicline addresses smoking cessation and nicotine dependence, supporting a coherent long-term investment in one defined clinical opportunity.
Expanded Funding FlexibilityThe ATM program increases access to capital for advancing the lead asset and funding a further Phase 3 study. That flexibility may help sustain clinical execution and prepare commercialization activities over the next several quarters, although use of the facility could dilute shareholders.
Governance ContinuityContinued board representation, auditor ratification, and shareholder approval of executive compensation provide governance and oversight continuity during an important development phase. Stable oversight can support execution discipline as the company funds trials and prepares its commercialization plans.
Bears Say
No Commercial RevenueWith no product revenue, Achieve cannot currently fund operations through customers or established commercial demand. Its financial outlook therefore remains dependent on successful clinical development and eventual approval, leaving revenue visibility highly uncertain over the next several quarters.
Widening Losses And Cash BurnLarge and persistent losses consume capital while the company remains pre-commercial, and negative free cash flow means operations are not self-funding. The multi-year burn pattern increases dependence on additional financing and could constrain the pace or scope of development activities.
Negative Equity And Dilution RiskNegative equity signals a materially weakened capital structure and reduces financial flexibility while Achieve funds clinical programs. Combined with the expanded share authorization and ATM capacity, the company has greater financing options but shareholders face meaningful potential dilution.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $2.62 and its highest was $8.64 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Achieve Life Sciences Inc’s market cap is $873.64M.
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Nov 05, 2026 which is in 56 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Aug 10, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.165 by -$0.635.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -0.2.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 102,902,490 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.165. Following the earnings report the stock price went up 0.301%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.17 (73.40% Upside)
$14.17 (73.40% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 86%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
167.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
223.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
ACHV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$14.17
▲(73.40% Upside)
Technical Analysis
Vanda
―
Minerva Neurosciences
―
Anavex Life Sciences
―
AC Immune SA
―
Ovid Therapeutics
―
Ownership Overview
0.35% Insiders
4.24% Mutual Funds
46.90% Other Institutional Investors
37.39% Public Companies and Individual Investors